Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has a beta value of 2.5 and has seen 3,143,457 shares traded in the recent trading session. The company, currently valued at $89.08 Million, closed the recent trade at $1.21 per share which meant it gained $0.03 on the day or 2.12% during that session. The ADMP stock price is -24.79% off its 52-week high price of $1.51 and 77.69% above the 52-week low of $0.27. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.9 Million shares traded. The 3-month trading volume is 5.35 Million shares.

The consensus among analysts is that Adamis Pharmaceuticals Corporation (ADMP) is an Overweight stock at the moment, with a recommendation rating of 2.3. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 3 have rated it as a Hold, with 2 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.08.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) trade information

Sporting 2.12% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Aug 05 when the ADMP stock price touched $1.3 or saw a rise of 7%. Year-to-date, Adamis Pharmaceuticals Corporation shares have moved 72.62%, while the 5-day performance has seen it change -4.05%. Over the past 30 days, the shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) have changed 109.39%. Short interest in the company has seen 4.51 Million shares shorted with days to cover at 0.84.

Wall Street analysts have a consensus price target for the stock at $1.25, which means that the shares’ value could jump 3.31% from current levels. The projected low price target is $1 while the price target rests at a high of $1.5. In that case, then, we find that the current price level is +23.97% off the targeted high while a plunge would see the stock lose -17.36% from current levels.

Adamis Pharmaceuticals Corporation (ADMP) estimates and forecasts

Figures show that Adamis Pharmaceuticals Corporation shares have underperformed across the wider relevant industry. The company’s shares have gained +70.27% over the past 6 months, with this year growth rate of -47.27%, compared to 12.4% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 50% and 66.7% for the next quarter. Revenue growth from the last financial year stood is estimated to be +16.5%.

3 analysts offering their estimates for the company have set an average revenue estimate of $5.27 Million for the current quarter. 3 have an estimated revenue figure of $8.63 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $5.76 Million and $6.37 Million respectively for this quarter and the next, and analysts expect sales will grow by -8.6% for the current quarter and 35.5% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +9.1% over the past 5 years. Earnings growth for 2020 is a modest +44.9%.